Changes in the liver transplant evaluation process during the early COVID-19 era and the role of telehealth

Table 3 Univariable and multivariable linear regression evaluating predictors of time to committee review during coronavirus disease 2019 era

	Univariable beta	P value	Multivariable beta	P value
Age	0.41	0.12
Sex, male	-14.6	0.03	-15.38	0.02
Preferred language, non-English	10.99	0.18
Race/ethnicity (ref: White)
Hispanic	-0.56	0.06	1.18	0.86
Asian	23.22	0.5	14.6	0.2
Other	-10.48	0.94	-8.92	0.53
Insurance (ref: Private)
Medicare	-21.91	0.005	-17.11	0.02
Medi-cal	-9.46	0.25	-4.84	0.55
Hepatology visit type (ref: Office visit)
Telehealth	5.4	0.5	1.48	0.85
Inpatient	-31.9	< 0.001	-36.7	< 0.001
MELD-Na at evaluation	-1.12	< 0.001	0.34	0.43
Distance to Stanford Hospital	-0.008	0.84
Alcohol etiology	8.05	0.22
HCC diagnosis	1.9	0.81

MELD-Na: Model for end-stage liver disease with sodium; HCC: Hepatocellular carcinoma.